Some history and some evidence from Australia

Professor Joanne Aitken Cancer Council Queensland









- <u>For the patient</u>, diagnosis and treatment at an early point in the course of the disease reduces the risk of melanoma metastasis and death.
- <u>For the population</u>, the goal is to reduce mortality from melanoma by reducing the incidence of late stage disease.



<u>For the population</u>, the goal is to reduce mortality from melanoma by reducing the incidence of late stage disease.

Does population screening for melanoma

- 1. reduce the incidence of late stage disease?
- 2. reduce melanoma mortality?

Evidence from two approaches:

- 1. Pilot study of a randomised controlled trial of a population screening program for melanoma.
- 2. Case-control study of melanoma screening.

Randomised trial of a population screening program for melanoma



Randomised trial of a population screening program for melanoma – PILOT STUDY





Melanoma Screening Trial SkinWatch population screening program







3-year population screening program:

- Free, open-access skin screening clinics
 Letters of invitation to <u>all</u> residents 30-79 yrs
- Community awareness program

 Local volunteer SkinWatch champion
 Community talks
 News and radio columns/advertisements
 SkinWatch community events
- Support program for local GPs Diagnostic decision tree Continuing medical education, clinical audit points SkinWatch resources for patients

Lowe, Ball et al, Health Promot Internation, 2004



Former Australian cricket Captain





In screening towns, 50% of people aged ≥ 30 years had at least one whole-body skin check by their GP or a *SkinWatch* doctor during the 3 year screening program.

Janda, Lowe et al, Cancer Causes Control, 2006



Aitken, Janda et al, J Am Acad Dermatol, 2006

Melanoma incidence (in situ + invasive) in 9 screening and 9 control towns



Melanoma incidence by thickness in 9 screening towns



Randomised trial of a population-based screening program for melanoma – PILOT STUDY

9 towns - **35,000** adults ≥**30**yrs

3-year screening program

60% of adults to have at least one wholebody skin check by a doctor by the end of the 3 year program.

18 Queensland towns

63,000 adults ≥30 yrs

9 towns - 28,000 adults ≥30yrs

control - normal practice

.....

Evidence from two approaches:

- 1. Pilot study of a randomised controlled trial of a population screening program for melanoma.
- 2. Case-control study of melanoma screening.



Hypotheses

- people with thicker tumours are LESS LIKELY to have been diagnosed by screening, or to have had a skin screening exam in the 3yrs before symptoms.
- people with thinner tumours are MORE LIKELY to have been diagnosed by screening, or to have had a skin screening exam in the 3yrs before symptoms.

What is the association between tumour thickness and screening history?

Case-control study of melanoma screening

Melanoma thickness at diagnosis	Sample	Diagnosed on screening, or had a full-body skin screening exam by a doctor in the 3 years before symptoms
Controls	3,824	
≤0.75mm	2,049	
0.76-1.49mm	1,017	
1.50-2.99mm	443	
≥3.00mm	253	

Case-control study of melanoma screening

Melanoma thickness at diagnosis	Sample	Diagnosed on screening, or had a full-body skin screening exam by a doctor in the 3 years before symptoms
Controls	3,824	28.3%
≤0.75mm	2,049	38.7%
≥3.00mm	253	22.5%

Melanoma thickness at diagnosis	Sample	Adjusted odds ratio	For people screened in the 3-year 'screening window', the likelihood of diagnosis in this thickness category was
Controls	3,824	<u>1.00</u>	
≤0.75mm	2,049	1.38 (1.22,1.56)	38% more likely
≥3.00mm	253	0.60 (0.43,0.83)	40% less likely

Adjusted for age, sex, education, employment status, marital status, hair colour, eye colour, skin type, number of moles on back, family history of melanoma, family history of other skin cancer, lifetime sun exposure, ethic status.

Melanoma thickness at diagnosis	Sample	Adjusted odds ratio	For people screened in the 3-year 'screening window', the likelihood of diagnosis in this thickness category was
Controls	3,824	<u>1.00</u>	
≤0.75mm	2,049	1.38 (1.22,1.56)	38% more likely
0.76-1.49mm	1,017	0.93 (0.79,1.10)	7% less likely
1.50-2.99mm	443	0.84 (0.67,1.07)	16% less likely
≥3.00mm	253	0.60 (0.43,0.83)	40% less likely

Adjusted for age, sex, education, employment status, marital status, hair colour, eye colour, skin type, number of moles on back, family history of melanoma, family history of other skin cancer, lifetime sun exposure, ethic status.

Aitken, Elwood et al, Int J Cancer, 2009



Does population screening for melanoma reduce the incidence of late stage disease?

YES. Screening reduces the incidence of thick melanomas.

Does population screening for melanoma reduce the incidence of late stage disease?

YES. Screening reduces the incidence of thick melanomas.

AND increases the incidence of thin melanomas because of:

- (i) *earlier diagnosis* of melanomas that would otherwise have been diagnosed at a more advanced stage
- (ii) *over-diagnosis* of lesions that would otherwise have not been detected, would not have progressed and would have had no impact on the patient's life.

Does population screening for melanoma reduce melanoma mortality?

No direct evidence.

If screening reduces the incidence of thick melanomas, then YES.

By how much? By enough to justify <u>the cost</u>?

 cost-effectiveness depends on the prevalence of melanoma in the target population; the cost, specificity and sensitivity of the screening exam; the cost of treating non-melanoma skin cancers; the cost of treating late stage melanoma... Does population screening for melanoma reduce melanoma mortality?

No direct evidence.

If screening reduces the incidence of thick melanomas, then YES.

By how much? By enough to justify <u>the cost</u>?

What reduction in melanoma mortality do we think is worthwhile?

Thank you

